Background and Aims: Upper gastrointestinal bleeding (UGB) is an important precipitating factor for the development of hepatic encephalopathy (HE) in cirrhotic patients. The aim of this study was to evaluate the efficacy of lactulose in a controlled randomized trial for prophylaxis of HE after UGB. Patients and Methods: 128 cirrhotic patients with UGB were consecutively classified according to Child-Pugh criteria and randomized to receive lactulose (group A, n = 63) or no lactulose (group B, n = 65) treatment after the symptoms of active bleeding disappeared. Curative effects were observed for 6 days. Results: Two patients in group A and 11 in group B had developed HE; the incidence rates were 3.2 and 16.9% (χ2 5.2061, p < 0.05). After treatment, a significant increase in ammonia level and higher number connection test (NCT) in the non-lactulose group, median blood ammonia levels (60.0 vs. 52.0), p < 0.05, and median NCT (43 vs. 38), p < 0.05, were observed. Patients who had developed HE had a significantly higher baseline Child-Turcotte-Pugh score (10.15 ±1.82 vs. 6.35 ± 1.60, p < 0.05), alanine aminotransferase (111.25 ± 91.62 vs. 48.32 ± 47.45, p < 0.05), aspartate aminotransferase (171.42 ± 142.68 vs. 46.33 ± 42.68, p < 0.05), total bilirubin (73.44 ± 47.20 vs. 29.75 ± 22.08, p < 0.05), serum albumin (24.65 ± 5.04 vs. 33.43 ± 6.49, p < 0.05), plasma prothrombin time (22.18 ± 4.60 vs. 17.12 ± 4.62, p < 0.05), and lower hemoglobin level (72.31 ± 15.15 vs. 87.45 ± 19.79, p < 0.05) as compared to patients who did not develop HE. On unconditional logistic regression analysis, patients who had developed HE were significantly associated with a higher baseline Child-Turcotte-Pugh score (OR 9.92, 95% CI 1.94-50.63, p < 0.05) and lactulose therapy (OR 0.02, 95% CI 0-0.74, p < 0.05) but were not associated with other parameters. Conclusions: Lactulose is an effective prophylaxis agent of HE for cirrhotic patients who had developed UGB.

Journal Section:
Original Paper
Keywords:
Cirrhosis, Upper gastrointestinal bleeding, Hepatic encephalopathy, Lactulose
1.
Bajaj JS, Wade JB, Sanyal AJ: Spectrum of neurocognitive impairment in cirrhosis: implications for the assessment of hepatic encephalopathy. Hepatology 2009;50:2014-2021.
[PubMed]
https://doi.org/10.1002/hep.23216
2.
Amodio P, Del Piccolo F, Petteno E, et al: Prevalence and prognostic value of quantified electroencephalogram alterations in cirrhosis patients. J Hepatol 2001;35:37-45.
[PubMed]
https://doi.org/10.1016/S0168-8278(01)00129-5
3.
Romero-Gomez M, Boza F, Garcia-Valdecasas MS, et al: Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Am J Gastroenterol 2001;96:2718-2723.
[PubMed]
https://doi.org/10.1111/j.1572-0241.2001.04130.x
4.
Munoz SJ: Hepatic encephalopathy. Med Clin North Am 2008;92:795-812.
[PubMed]
https://doi.org/10.1016/j.mcna.2008.03.009
5.
Sundaram V, Shaikh OS: Hepatic encephalopathy: pathophysiology and emerging therapies. Med Clin North Am 2009;93:819-836.
[PubMed]
https://doi.org/10.1016/j.mcna.2009.03.009
6.
Cales P, Zabotto B, Meskens C, et al: Gastroesophageal endoscopic features in cirrhosis. Observer variability, inter-associations, and relationship to hepatic dysfunction. Gastroenterology 1990;98:156-162.
[PubMed]
7.
Hassan SN, Townsend JL, Curry SB, et al: Hepatic encephalopathy: a retrospective analysis. J Natl Med Assoc 1982;74:521-523.
[PubMed]
8.
Sharma BC, Sharma P, Agrawal A, et al: Secondary prophylaxis of hepatic encephalopathy: an open-label. randomized controlled trial of lactulose versus placebo. Gastroenterology 2009;137:885-891.
[PubMed]
https://doi.org/10.1053/j.gastro.2009.05.056
9.
Blei AT, Cordoba J, for the Practice Parameters Committee of the American College of Gastroenterology: Hepatic encephalopathy. Am J Gastroenterol 2001;96:1968-1976.
[PubMed]
https://doi.org/10.1111/j.1572-0241.2001.03964.x
10.
Riordan SM, Williams R: Treatment of hepatic encephalopathy. N Engl J Med 1997;337:473-479.
[PubMed]
https://doi.org/10.1056/NEJM199708143370707
11.
Bouhnik Y, Attar A, Joly FA, et al: Lactulose ingestion increases faecal bifidobacterial counts: a randomised double-blind study in healthy humans. Eur J Clin Nutr 2004;58:462-466.
[PubMed]
https://doi.org/10.1038/sj.ejcn.1601829
12.
Poordad FF: The burden of hepatic encephalopathy. Aliment Pharmacol Ther 2007;25(suppl 1):3-9.
[PubMed]
https://doi.org/10.1111/j.1746-6342.2006.03215.x
13.
Munoz SJ: Hepatic encephalopathy. Med Clin North Am 2008;92:795-812.
[PubMed]
https://doi.org/10.1016/j.mcna.2008.03.009
14.
Sharma P, Agrawal A, Sharma BC, et al: Prophylaxis of hepatic encephalopathy in acute variceal bleed: a randomized controlled trial of lactulose versus no lactulose. J Gastroenterol Hepatol 2011;26:996-1003.
[PubMed]
https://doi.org/10.1111/j.1440-1746.2010.06596.x
15.
Butterworth RF: The neurobiology of hepatic encephalopathy. Semin Liver Dis 1996;16:235-244.
[PubMed]
https://doi.org/10.1055/s-2007-1007236
16.
Vaquero J, Chung C, Blei AT: Brain edema in acute liver failure. A window to the pathogenesis of hepatic encephalopathy. Ann Hepatol 2003;2:12-22.
[PubMed]
17.
Foster KJ, Lin S, Turck CJ: Current and emerging strategies for treating hepatic encephalopathy. Crit Care Nurs Clin North Am 2010;22:341-350.
[PubMed]
https://doi.org/10.1016/j.ccell.2010.04.007
18.
Weber FL Jr: Effects of lactulose on nitrogen metabolism. Scand J Gastroenterol Suppl 1997;222:83-87.
[PubMed]
19.
Zheng Z: Gastroenterology, ed 3. Beijing, People's Health Publishing House, 2000, pp 914-939.
20.
Tromm A, Griga T, Greving I, et al: Orthograde whole gut Irrigation with mannite versus paromomycin + lactulose as prophylaxis of hepatic encephalopathy in patients with cirrhosis and upper gastrointestinal bleeding: results of a controlled randomized trial. Hepatogastroenterology 2000;47:473-477.
[PubMed]
© 2013 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2013
You do not currently have access to this content.